Stitt J A
Department of Human Oncology, University of Wisconsin, Madison.
Oncology (Williston Park). 1992 Jan;6(1):59-70, 79; discussion 80-2.
High-dose-rate intracavitary radiation (HDR-ICR) for gynecologic brachytherapy has developed clinically over the past 15 to 20 years in Europe and Asia and is becoming more prevalent in North America. Brachytherapy given at dose rates of 0.5 to 5.0 Gy/minute means that an intracavitary procedure that previously required hospitalization and bed rest for several days can be administered over a short time on an outpatient basis. High-dose-rate remote afterloading brachytherapy has brought about the development of new computer-controlled treatment units, modification of treatment techniques for outpatient therapy, altered dose schedules of external beam and intracavitary irradiation, and revised dose specification definitions. A review of the literature on high-dose-rate brachytherapy for cervical and endometrial carcinoma demonstrates that local control, survival, and acute and late sequelae are comparable to traditional low-dose-rate brachytherapy.
高剂量率腔内放射治疗（HDR-ICR）用于妇科近距离放疗，在过去15至20年里已在欧洲和亚洲得到临床应用，并且在北美也越来越普遍。以0.5至5.0 Gy/分钟的剂量率进行近距离放疗意味着，以前需要住院并卧床休息数天的腔内治疗现在可以在门诊短时间内完成。高剂量率遥控后装近距离放疗推动了新型计算机控制治疗设备的发展、门诊治疗技术的改进、外照射和腔内照射剂量方案的改变以及剂量规范定义的修订。对有关子宫颈癌和子宫内膜癌高剂量率近距离放疗的文献综述表明，局部控制、生存率以及急性和晚期后遗症与传统低剂量率近距离放疗相当。
